You are here: Home › Research › Labs › Federico Innocenti Lab › Publications

Publications

  1. A Genome-Wide Association Study of Overall Survival in Pancreatic Cancer Patients Treated with Gemcitabine in CALGB 80303. Innocenti F, Owzar K, Cox NL, Evans P, Kubo M, Zembutsu H, Jiang C, Hollis D, Mushiroda T, Li L, Friedman P, Wang L, Glubb D, Hurwitz H, Giacomini KM, McLeod HL, Goldberg RM, Schilsky RL, Kindler HL, Nakamura Y, Ratain MJ. Clin Cancer Res. 2012 Jan 15;18(2):577-584. Epub 2011 Dec 5. PMID: 22142827 [PubMed - as supplied by publisher]
  2. The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients. Ramírez J, Wu K, Janisch L, Karrison T, House LK, Innocenti F, Cohen EE, Ratain MJ. Cancer Chemother Pharmacol. 2011 Dec;68(6):1629-32. Epub 2011 Aug 23. PMID: 21861128 [PubMed - indexed for MEDLINE]
  3. Recent progress and clinical importance on pharmacogenetics in cancer therapy. Soh TI, Yong WP, Innocenti F. Clin Chem Lab Med. 2011 Oct;49(10):1621-32. Epub 2011 Sep 28. PMID: 21950596 [PubMed - in process]
  4. Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. Glubb DM, Cerri E, Giese A, Zhang W, Mirza O, Thompson EE, Chen P, Das S, Jassem J, Rzyman W, Lingen MW, Salgia R, Hirsch FR, Dziadziuszko R, Ballmer-Hofer K, Innocenti F. Clin Cancer Res. 2011 Aug 15;17(16):5257-67. doi: 10.1158/1078-0432.CCR-11-0379. Epub 2011 Jun 28. PMID: 21712447 [PubMed - in process]
  5. Genetic Analysis in Translational Medicine: The 2010 GOLDEN HELIX Symposium. Patrinos GP, Innocenti F, Cox N, Fortina P. Hum Mutat. 2011 Jun;32(6):698-703. doi: 10.1002/humu.21473. Epub 2011 Mar 24. PMID: 21438074 [PubMed - indexed for MEDLINE]
  6. Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue. Innocenti F, Cooper GM, Stanaway IB, Gamazon ER, Smith JD, Mirkov S, Ramirez J, Liu W, Lin YS, Moloney C, Aldred SF, Trinklein ND, Schuetz E, Nickerson DA, Thummel KE, Rieder MJ, Rettie AE, Ratain MJ, Cox NJ, Brown CD. PLoS Genet. 2011 May;7(5):e1002078. Epub 2011 May 26. PMID: 21637794 [PubMed - indexed for MEDLINE]
  7. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. O'Donnell PH, Artz AS, Undevia SD, Pai RK, Del Cerro P, Horowitz S, Godley LA, Hart J, Innocenti F, Larson RA, Odenike OM, Stock W, Van Besien K. Leuk Lymphoma. 2010 Dec; 51(12):2240-9. Epub 2010 Oct 4. PMID: 20919852 [PubMed - in process]
  8. Mechanisms of genetic regulation in gene expression: examples from drug metabolizing enzymes and transporters. Glubb DM, Innocenti F. Wiley Interdiscip Rev Syst Biol Med. 2010 Sep 23. [Epub ahead of print] PMID: 20865777 [PubMed - as supplied by publisher]
  9. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM. J Clin Oncol. 2010 Aug 1; 28(22):3617-22. Epub 2010 Jul 6. PMID: 20606091 [PubMed - indexed for MEDLINE]
  10. The use of genomic information to optimize cancer chemotherapy. Innocenti F, Cox NJ, Dolan ME. Semin Oncol. 2011 Apr;38(2):186-95. Review. PMID: 21421109 [PubMed - indexed for MEDLINE]
  11. Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy. Ramírez J, Ratain MJ, Innocenti F. Future Oncol. 2010 Apr; 6(4):563-85. Review. PMID: 20373870 [PubMed - indexed for MEDLINE]
  12. Pharmacogenomics: paving the path to personalized medicine. Patrinos GP, Innocenti F. Pharmacogenomics. 2010 Feb; 11(2):141-6. PMID: 20136354 [PubMed - indexed for MEDLINE]
  13. Individualizing dosing of irinotecan. Ratain MJ, Innocenti F. Clin Cancer Res. 2010 Jan 15; 16(2):371-2. Epub 2010 Jan 12. PMID: 20068075 [PubMed - indexed for MEDLINE]
  14. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. Toffoli G, Cecchin E, Gasparini G, D'Andrea M, Azzarello G, Basso U, Mini E, Pessa S, De Mattia E, Lo Re G, Buonadonna A, Nobili S, De Paoli P, Innocenti F. J Clin Oncol. 2010 Feb 10; 28(5):866-71. Epub 2009 Dec 28. PMID: 20038727 [PubMed - indexed for MEDLINE]
  15. Translating the cancer genome into clinically useful tools and strategies. Innocenti F, Schilsky RL. Dis Model Mech. 2009 Sep-Oct; 2(9-10):426-9. No abstract available. PMID: 19726797 [PubMed - indexed for MEDLINE]
  16. Ethnic differences and functional analysis of MET mutations in lung cancer. Krishnaswamy S, Kanteti R, Duke-Cohan JS, Loganathan S, Liu W, Ma PC, Sattler M, Singleton PA, Ramnath N, Innocenti F, Nicolae DL, Ouyang Z, Liang J, Minna J, Kozloff MF, Ferguson MK, Natarajan V, Wang YC, Garcia JG, Vokes EE, Salgia R. Clin Cancer Res. 2009 Sep 15; 15(18):5714-23. Epub 2009 Sep 1. PMID: 19723643 [PubMed - indexed for MEDLINE]
  17. Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan. Hoskins JM, Rosner GL, Ratain MJ, McLeod HL, Innocenti F. Pharmacogenomics. 2009 Jul; 10(7):1139-46. PMID: 19604089 [PubMed - indexed for MEDLINE]
  18. Clinical pharmacology and pharmacogenetics of gemcitabine. Wong A, Soo RA, Yong WP, Innocenti F. Drug Metab Rev. 2009; 41(2):77-88. Review. PMID: 19514966 [PubMed - indexed for MEDLINE]
  19. R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9. Yong WP, Kim TW, Undevia SD, Innocenti F, Ratain MJ. Eur J Cancer. 2009 Jul; 45(11):1904-8. Epub 2009 May 21. PMID: 19464879 [PubMed - indexed for MEDLINE]
  20. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramírez J, Relling M, Chen P, Das S, Rosner GL, Ratain MJ. J Clin Oncol. 2009 Jun 1; 27(16):2604-14. Epub 2009 Apr 6. PMID: 19349540 [PubMed - indexed for MEDLINE]
  21. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. Cecchin E, Innocenti F, D'Andrea M, Corona G, De Mattia E, Biason P, Buonadonna A, Toffoli G. J Clin Oncol. 2009 May 20; 27(15):2457-65. Epub 2009 Apr 13. PMID: 19364970 [PubMed - indexed for MEDLINE]
  22. The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds. Innocenti F, Mirkov S, Nagasubramanian R, Ramírez J, Liu W, Bleibel WK, Shukla SJ, Hennessy K, Rosner GL, Cook E Jr, Eileen Dolan M, Ratain MJ. Cancer Chemother Pharmacol. 2009 Apr; 63(5):881-7. Epub 2008 Aug 2. PMID: 18677484 [PubMed - indexed for MEDLINE]
  23. A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours. Undevia SD, Innocenti F, Ramirez J, House L, Desai AA, Skoog LA, Singh DA, Karrison T, Kindler HL, Ratain MJ. Eur J Cancer. 2008 Aug; 44(12):1684-92. Epub 2008 Jul 21. PMID: 18650079 [PubMed - indexed for MEDLINE]
  24. Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene. Innocenti F, Liu W, Fackenthal D, Ramírez J, Chen P, Ye X, Wu X, Zhang W, Mirkov S, Das S, Cook E Jr, Ratain MJ. Pharmacogenet Genomics. 2008 Aug; 18(8):683-97. PMID: 18622261 [PubMed - indexed for MEDLINE]
  25. Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet? Perera MA, Innocenti F, Ratain MJ. Pharmacotherapy. 2008 Jun; 28(6):755-68. Review. PMID: 18503403 [PubMed - indexed for MEDLINE]
  26. Pharmacogenetic pathway analysis of irinotecan. Rosner GL, Panetta JC, Innocenti F, Ratain MJ. Clin Pharmacol Ther. 2008 Sep; 84(3):393-402. Epub 2008 Apr 16. PMID: 18418374 [PubMed - indexed for MEDLINE]
  27. Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Liu W, Wu X, Zhang W, Montenegro RC, Fackenthal DL, Spitz JA, Huff LM, Innocenti F, Das S, Cook EH Jr, Cox NJ, Bates SE, Ratain MJ. Clin Cancer Res. 2007 Nov 15; 13(22 Pt 1):6788-95. PMID: 18006781 [PubMed - indexed for MEDLINE]
  28. Translation of pharmacogenetic knowledge into cancer therapeutics. Yong WP, Innocenti F. Clin Adv Hematol Oncol. 2007 Sep; 5(9):698-706. Review. PMID: 17982411 [PubMed - indexed for MEDLINE]
  29. Lack of association between common polymorphisms in UGT1A9 and gene expression and activity. Ramírez J, Liu W, Mirkov S, Desai AA, Chen P, Das S, Innocenti F, Ratain MJ. Drug Metab Dispos. 2007 Dec; 35(12):2149-53. Epub 2007 Aug 30. PMID: 17761781 [PubMed - indexed for MEDLINE]
  30. Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma. Corona G, Vaccher E, Sandron S, Sartor I, Tirelli U, Innocenti F, Toffoli G. Clin Pharmacol Ther. 2008 Apr; 83(4):601-6. Epub 2007 Aug 22. PMID: 17713471 [PubMed - indexed for MEDLINE]
  31. UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers. Yoder Graber AL, Ramírez J, Innocenti F, Ratain MJ. Pharmacogenet Genomics. 2007 Aug; 17(8):619-27. PMID: 17622938 [PubMed - indexed for MEDLINE]
  32. Insights, challenges, and future directions in irinogenetics. Kim TW, Innocenti F. Ther Drug Monit. 2007 Jun; 29(3):265-70. Review. PMID: 17529881 [PubMed - indexed for MEDLINE]
  33. Searching for tissue-specific expression pattern-linked nucleotides of UGT1A isoforms. Zhang W, Liu W, Innocenti F, Ratain MJ. PLoS One. 2007 Apr 25; 2(4):e396. PMID: 17460763 [PubMed - indexed for MEDLINE]
  34. Hepatocyte nuclear factor-1 alpha is associated with UGT1A1, UGT1A9 and UGT2B7 mRNA expression in human liver. Ramírez J, Mirkov S, Zhang W, Chen P, Das S, Liu W, Ratain MJ, Innocenti F. Pharmacogenomics J. 2008 Apr; 8(2):152-61. Epub 2007 Apr 17. PMID: 17440429 [PubMed - indexed for MEDLINE]
  35. Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer. Yong WP, Desai AA, Innocenti F, Ramirez J, Shepard D, Kobayashi K, House L, Fleming GF, Vogelzang NJ, Schilsky RL, Ratain MJ. Cancer Chemother Pharmacol. 2007 Nov; 60(6):811-9. Epub 2007 Feb 17. PMID: 17308893 [PubMed - indexed for MEDLINE]
  36. Challenges in the development and use of pharmacogenomic markers in oncology. Innocenti F. J Support Oncol. 2007 Jan; 5(1):15-6. Review. No abstract available. PMID: 17265781 [PubMed - indexed for MEDLINE]
  37. The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. Ramchandani RP, Wang Y, Booth BP, Ibrahim A, Johnson JR, Rahman A, Mehta M, Innocenti F, Ratain MJ, Gobburu JV. J Clin Pharmacol. 2007 Jan; 47(1):78-86. PMID: 17192505 [PubMed - indexed for MEDLINE]
  38. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Innocenti F, Ratain MJ. Pharmacogenomics. 2006 Dec; 7(8):1211-21. PMID: 17184208 [PubMed - indexed for MEDLINE]
  39. Effects of green tea compounds on irinotecan metabolism. Mirkov S, Komoroski BJ, Ramírez J, Graber AY, Ratain MJ, Strom SC, Innocenti F. Drug Metab Dispos. 2007 Feb; 35(2):228-33. Epub 2006 Nov 15. PMID: 17108060 [PubMed - indexed for MEDLINE]
  40. MTHFR and ALL risk: a challenge. Toffoli G, Innocenti F. Leuk Lymphoma. 2006 Jul; 47(7):1203-4. No abstract available. PMID: 16923547 [PubMed - indexed for MEDLINE]
  41. The role of pharmacogenetics in cancer therapeutics. Yong WP, Innocenti F, Ratain MJ. Br J Clin Pharmacol. 2006 Jul; 62(1):35-46. Review. PMID: 16842377 [PubMed - indexed for MEDLINE]
  42. Irinogenetics: what is the right star? Innocenti F, Vokes EE, Ratain MJ. J Clin Oncol. 2006 May 20; 24(15):2221-4. Epub 2006 Apr 24. No abstract available. PMID: 16636339 [PubMed - indexed for MEDLINE]
  43. Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: a phase I-II study. Tibaldi C, Prochilo T, Russo F, Pennucci MC, Del Freo A, Innocenti F, Fabbri A, Falcone A, Conte PF, Baldini E. Br J Cancer. 2006 May 8; 94(9):1263-6. PMID: 16622468 [PubMed - indexed for MEDLINE]
  44. UGT1A1 genotyping in patients undergoing treatment with irinotecan. Innocenti F. Clin Adv Hematol Oncol. 2005 Nov; 3(11):843-4. No abstract available. PMID: 16491625 [PubMed - indexed for MEDLINE]
  45. Study of the genetic determinants of UGT1A1 inducibility by phenobarbital in cultured human hepatocytes. Ramírez J, Komoroski BJ, Mirkov S, Graber AY, Fackenthal DL, Schuetz EG, Das S, Ratain MJ, Innocenti F, Strom SC. Pharmacogenet Genomics. 2006 Feb; 16(2):79-86. PMID: 16424820 [PubMed - indexed for MEDLINE]
  46. Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes. Yong WP, Ramirez J, Innocenti F, Ratain MJ. Clin Cancer Res. 2005 Sep 15; 11(18):6699-704. PMID: 16166450 [PubMed - indexed for MEDLINE]
  47. Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes. Innocenti F, Liu W, Chen P, Desai AA, Das S, Ratain MJ. Pharmacogenet Genomics. 2005 May; 15(5):295-301. PMID: 15864130 [PubMed - indexed for MEDLINE]
  48. 5-Fluorouracil catabolism to 5-fluoro-5,6-dihydrouracil is reduced by acute liver impairment in mice. Innocenti F, Danesi R, Bocci G, Natale G, Del Tacca M. Toxicol Appl Pharmacol. 2005 Mar 1; 203(2):106-13. PMID: 15710171 [PubMed - indexed for MEDLINE]
  49. Linkage disequilibrium across the UGT1A locus should not be ignored in association studies of cancer susceptibility. Liu W, Innocenti F, Ratain MJ. Clin Cancer Res. 2005 Feb 1; 11(3):1348-9; author reply 1349. No abstract available. PMID: 15709208 [PubMed - indexed for MEDLINE]
  50. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Liu W, Innocenti F, Wu MH, Desai AA, Dolan ME, Cook EH Jr, Ratain MJ. Cancer Res. 2005 Jan 1; 65(1):46-53. PMID: 15665278 [PubMed - indexed for MEDLINE]
  51. A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital. Innocenti F, Undevia SD, Ramírez J, Mani S, Schilsky RL, Vogelzang NJ, Prado M, Ratain MJ. Clin Pharmacol Ther. 2004 Nov; 76(5):490-502. PMID: 15536463 [PubMed - indexed for MEDLINE]
  52. CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Ramírez J, Innocenti F, Schuetz EG, Flockhart DA, Relling MV, Santucci R, Ratain MJ. Drug Metab Dispos. 2004 Sep; 32(9):930-6. PMID: 15319333 [PubMed - indexed for MEDLINE]
  53. A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer. Desai AA, Innocenti F, Janisch L, DeMario M, Shepard D, Ramirez J, Fleming GF, Ratain MJ. Cancer Chemother Pharmacol. 2004 Nov; 54(5):377-84. Epub 2004 Jul 3. PMID: 15235824 [PubMed - indexed for MEDLINE]
  54. "Irinogenetics" and UGT1A: from genotypes to haplotypes. Innocenti F, Ratain MJ. Clin Pharmacol Ther. 2004 Jun; 75(6):495-500. Review. No abstract available. PMID: 15179404 [PubMed - indexed for MEDLINE]
  55. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramírez J, Rudin CM, Vokes EE, Ratain MJ. J Clin Oncol. 2004 Apr 15; 22(8):1382-8. Epub 2004 Mar 8. PMID: 15007088 [PubMed - indexed for MEDLINE]
  56. Pharmacogenomics: road to anticancer therapeutics nirvana? Desai AA, Innocenti F, Ratain MJ. Oncogene. 2003 Sep 29; 22(42):6621-8. PMID: 14528287 [PubMed - indexed for MEDLINE]
  57. UGT pharmacogenomics: implications for cancer risk and cancer therapeutics. Desai AA, Innocenti F, Ratain MJ. Pharmacogenetics. 2003 Aug; 13(8):517-23. PMID: 12893990 [PubMed - indexed for MEDLINE]
  58. A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Sawyer MB, Innocenti F, Das S, Cheng C, Ramírez J, Pantle-Fisher FH, Wright C, Badner J, Pei D, Boyett JM, Cook E Jr, Ratain MJ. Clin Pharmacol Ther. 2003 Jun; 73(6):566-74. PMID: 12811366 [PubMed - indexed for MEDLINE]
  59. Irinotecan treatment in cancer patients with UGT1A1 polymorphisms. Innocenti F, Ratain MJ. Oncology (Williston Park). 2003 May; 17(5 Suppl 5):52-5. Review. PMID: 12800608 [PubMed - indexed for MEDLINE]
  60. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Liu W, Innocenti F, Chen P, Das S, Cook EH Jr, Ratain MJ. Clin Cancer Res. 2003 Mar; 9(3):1009-12. PMID: 12631599 [PubMed - indexed for MEDLINE]
  61. High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. Bengala C, Danesi R, Guarneri V, Pazzagli I, Donati S, Favre C, Fogli S, Biadi O, Innocenti F, Del Tacca M, Mariani M, Conte PF. Bone Marrow Transplant. 2003 Feb; 31(4):275-80. PMID: 12621462 [PubMed - indexed for MEDLINE]
  62. Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report. Bocci G, Danesi R, Allegrini G, Innocenti F, Di Paolo A, Falcone A, Conte PF, Del Tacca M. Eur J Clin Pharmacol. 2002 Dec; 58(9):593-5. PMID: 12602342 [PubMed - indexed for MEDLINE]
  63. Pharmacogenetics in cancer treatment. Nagasubramanian R, Innocenti F, Ratain MJ. Annu Rev Med. 2003; 54:437-52. Epub 2001 Dec 3. Review. PMID: 12525681 [PubMed - indexed for MEDLINE]
  64. Effect of methylenetetrahydrofolate reductase 677C-->T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Toffoli G, Russo A, Innocenti F, Corona G, Tumolo S, Sartor F, Mini E, Boiocchi M. Int J Cancer. 2003 Jan 20; 103(3):294-9. PMID: 12471611 [PubMed - indexed for MEDLINE]
  65. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Innocenti F, Grimsley C, Das S, Ramírez J, Cheng C, Kuttab-Boulos H, Ratain MJ, Di Rienzo A. Pharmacogenetics. 2002 Dec; 12(9):725-33. Erratum in: Pharmacogenetics. 2003 Mar; 13(3):183. PMID: 12464801 [PubMed - indexed for MEDLINE]
  66. In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes. Ramírez J, Iyer L, Journault K, Bélanger P, Innocenti F, Ratain MJ, Guillemette C. Pharm Res. 2002 May; 19(5):588-94. PMID: 12069159 [PubMed - indexed for MEDLINE]
  67. Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Innocenti F, Ratain MJ. Clin Cancer Res. 2002 May; 8(5):1314; author reply 1315-6. No abstract available. PMID: 12006555 [PubMed - indexed for MEDLINE]
  68. Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients. Danesi R, Innocenti F, Fogli S, Gennari A, Baldini E, Di Paolo A, Salvadori B, Bocci G, Conte PF, Del Tacca M. Br J Clin Pharmacol. 2002 May; 53(5):508-18. PMID: 11994057 [PubMed - indexed for MEDLINE]
  69. Update on pharmacogenetics in cancer chemotherapy. Innocenti F, Ratain MJ. Eur J Cancer. 2002 Mar; 38(5):639-44. Review. PMID: 11916544 [PubMed - indexed for MEDLINE]
  70. Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Innocenti F, Iyer L, Ramírez J, Green MD, Ratain MJ. Drug Metab Dispos. 2001 May; 29(5):686-92. PMID: 11302935 [PubMed - indexed for MEDLINE]
  71. Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan. Innocenti F, Iyer L, Ratain MJ. Drug Metab Dispos. 2001 Apr; 29(4 Pt 2):596-600. PMID: 11259359 [PubMed - indexed for MEDLINE]
  72. High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC). Bengala C, Pazzagli I, Innocenti F, Donati S, Favre C, Menconi MC, Greco F, Danesi R, Orlandini C, Guarneri V, Del Tacca M, Conte PF. Ann Oncol. 2001 Jan; 12(1):69-74. PMID: 11249051 [PubMed - indexed for MEDLINE]
  73. Pharmacogenetics: a tool for individualizing antineoplastic therapy. Innocenti F, Iyer L, Ratain MJ. Clin Pharmacokinet. 2000 Nov; 39(5):315-25. Review. PMID: 11108431 [PubMed - indexed for MEDLINE]
  74. Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea. Innocenti F, Stadler WM, Iyer L, Ramírez J, Vokes EE, Ratain MJ. Clin Cancer Res. 2000 Sep; 6(9):3400-5. PMID: 10999721 [PubMed - indexed for MEDLINE]
  75. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. Bocci G, Danesi R, Di Paolo AD, Innocenti F, Allegrini G, Falcone A, Melosi A, Battistoni M, Barsanti G, Conte PF, Del Tacca M. Clin Cancer Res. 2000 Aug; 6(8):3032-7. PMID: 10955781 [PubMed - indexed for MEDLINE]
  76. Variable correlation between 6-mercaptopurine metabolites in erythrocytes and hematologic toxicity: implications for drug monitoring in children with acute lymphoblastic leukemia. Innocenti F, Danesi R, Favre C, Nardi M, Menconi MC, Di Paolo A, Bocci G, Fogli S, Barbara C, Barachini S, Casazza G, Macchia P, Del Tacca M. Ther Drug Monit. 2000 Aug; 22(4):375-82. PMID: 10942174 [PubMed - indexed for MEDLINE]
  77. Manumycin inhibits ras signal transduction pathway and induces apoptosis in COLO320-DM human colon tumour cells. Di Paolo A, Danesi R, Nardini D, Bocci G, Innocenti F, Fogli S, Barachini S, Marchetti A, Bevilacqua G, Del Tacca M. Br J Cancer. 2000 Feb; 82(4):905-12. PMID: 10732765 [PubMed - indexed for MEDLINE]
  78. Metabolism of 6-mercaptopurine in the erythrocytes, liver, and kidney of rats during multiple-dose regimens. Innocenti F, Danesi R, Bocci G, Fogli S, Di Paolo A, Del Tacca M. Cancer Chemother Pharmacol. 1999; 43(2):133-40. PMID: 9923818 [PubMed - indexed for MEDLINE]
  79. Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo. Bocci G, Danesi R, Benelli U, Innocenti F, Di Paolo A, Fogli S, Del Tacca M. Cancer Chemother Pharmacol. 1999; 43(3):205-12. PMID: 9923550 [PubMed - indexed for MEDLINE]
  80. Chronic administration of suramin induces neurotoxicity in rats. Di Paolo A, Danesi R, Innocenti F, Bocci G, Nardini D, Fogli S, Pollina L, Rossi B, Del Tacca M. J Neurol Sci. 1997 Nov 25; 152(2):125-31. PMID: 9415531 [PubMed - indexed for MEDLINE]
  81. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer. Conte PF, Baldini E, Gennari A, Michelotti A, Salvadori B, Tibaldi C, Danesi R, Innocenti F, Gentile A, Dell'Anna R, Biadi O, Mariani M, Del Tacca M. J Clin Oncol. 1997 Jul; 15(7):2510-7. PMID: 9215819 [PubMed - indexed for MEDLINE]
  82. Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate. Innocenti F, Danesi R, Di Paolo A, Loru B, Favre C, Nardi M, Bocci G, Nardini D, Macchia P, Del Tacca M. Cancer Chemother Pharmacol. 1996; 37(5):409-14. PMID: 8599862 [PubMed - indexed for MEDLINE]
  83. Inhibitory effect of the somatostatin analogue SMS 201-995 and cytokines on the proliferation of human colon adenocarcinoma cell lines. di Paolo A, Bocci G, Innocenti F, Agen C, Nardini D, Danesi R, del Tacca M. Pharmacol Res. 1995 Sep; 32(3):135-9. PMID: 8745343 [PubMed - indexed for MEDLINE]
  84. Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice. Innocenti F, Danesi R, Di Paolo A, Agen C, Nardini D, Bocci G, Del Tacca M. Drug Metab Dispos. 1995 Jul; 23(7):713-7. PMID: 7587959 [PubMed - indexed for MEDLINE]
  85. Dissociation between in vitro cytotoxicity and in vivo cardiotoxicity of two new anthracyclines: 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin and 4'-deoxy-4'-iodo-doxorubicin. Pinna A, Agen C, Di Paolo A, Innocenti F, Nardini D, Danesi R, Del Tacca M. J Environ Pathol Toxicol Oncol. 1994; 13(1):25-31. PMID: 7823290 [PubMed - indexed for MEDLINE]
Document Actions